Personalized Preventive Support for Cognitive Impairment in Non-Metastatic Breast Cancer (EFACog)

Condition(s) studied

Investigational drug(s) / intervention(s)

Face to face and telephonic interviews: face to face interview : before the first chemotherapy treatment (M0), then at 3 months (M3), 6 months (M6) and 9 months (M9) after the first chemotherapy treatment. Telephonic interview : every month between two face-to-face interviews, i.e. at 1 month after the first treatment (M1), at 2 months (M2), at 4 months (M4), at 5 months (M5), at 7 months (M7) and at 8 months (M8) after the first chemotherapy treatment.

Study summary

EFACog is a single-center prospective cohort feasibility study conducted on a single group of patients to study the feasibility of a personalized support program by a nurse conducted over 9 months, using face-to-face and telephone interviews. The objective of this support program is to prevent the occurrence of post-chemotherapy cognitive impairment. After a pre-inclusion visit, patients with no pre-existing cognitive impairment will be included in the study and will receive a 9-month follow-up after the first course of chemotherapy. All follow-up visits (telephone or face-to-face) will be scheduled in conjunction with those taking place in the care setting.

Eligibility

Primary outcome measure(s)

• To assess program feasibility — 9 months
  Rate of patients who participated in all provider interviews (face-to-face and telephone contacts).

Trial sites (1)

More Institut de Cancérologie de Lorraine trials in France